JJP Biologics to Present Data Showing the Potential of Nebaprubart for Linear IgA Dermatosis (LAD) at Two Key Upcoming Scientific Conferences

Warsaw, Poland – September 28, 2026 – JJP Biologics, ("JJPBio" or the "Company") a clinical-stage, immune-focused biotech that engineers precision antibodies to correct derailed immune pathways that drive autoimmune diseases and cancer, today announced that data on nebaprubart, its investigational first-in-class anti-CD89 antagonist, will be presented as an oral presentation at the IPPF Scientific Symposium on Pemphigus and Pemphigoid being held 28-29 September in Lübeck, Germany, and as a poster presentation at the European Academy of Dermatology and Venereology (EADV) Congress being held 30 September – 3 October in Vienna, Austria.